Vijayan A, Franklin S C, Delmez J A, Miller S B
Renal Division, Department of Medicine, Washington University School of Medicine, St Louis, MO, USA.
Am J Kidney Dis. 2000 Jan;35(1):150-3. doi: 10.1016/S0272-6386(00)70322-2.
Insulin-like growth factor 1 (IGF1) has been shown to improve renal function in healthy subjects, as well as those with chronic renal failure. To our knowledge, IGF1 has not been shown to be efficacious in patients who were already undergoing dialysis. We present the case of a 70-year-old woman with end-stage renal disease (ESRD) and overt uremic symptoms treated with IGF1 after peritoneal dialysis was discontinued because of complications. There was a significant improvement in her inulin clearance during the course of treatment. The patient remained well and did not require dialytic support for 19 weeks. Although further data are necessary, we believe this case shows that IGF1 may be a short-term alternative to dialysis in patients with ESRD.
胰岛素样生长因子1(IGF1)已被证明可改善健康受试者以及慢性肾功能衰竭患者的肾功能。据我们所知,IGF1在已经接受透析的患者中尚未显示出疗效。我们报告一例70岁终末期肾病(ESRD)女性患者,因并发症停止腹膜透析后接受IGF1治疗,出现明显尿毒症症状。在治疗过程中,她的菊粉清除率有显著改善。该患者病情稳定,19周内无需透析支持。尽管还需要更多数据,但我们认为该病例表明,IGF1可能是ESRD患者透析的短期替代方法。